New Study Could Unlock How Body’s Emergency Blood Factory is Connected to Aging and Cancer
Emergency myelopoiesis is a vital process that rapidly generates immune cells in response to infections, injury, or surgery. However, when this emergency response remains active for too long, excessive white blood cell production and chronic inflammation can occur, contributing to accelerated aging and the development of diseases such as acute myeloid leukemia (AML).
Researchers led by Emmanuelle Passegué at Columbia University have identified a common molecular “on switch” that activates emergency myelopoiesis regardless of the triggering event. This discovery suggests that therapies aimed at turning off this single pathway may offer a more effective strategy for treating age-related inflammation and certain blood cancers.
Using advanced single-cell RNA sequencing and computational tools developed in collaboration with Raul Rabadan's team, researchers created HemaScribe and HemaScape, powerful platforms that map blood cell development and reveal how emergency myelopoiesis reshapes the blood system. These freely available tools are already helping scientists uncover new biological insights and identify potential drug targets.
The findings also reveal that many AML patients exhibit signatures of persistent emergency myelopoiesis, which is associated with poorer outcomes, suggesting that the process may be hijacked to drive more aggressive disease.
Researchers are now focused on applying these tools to study blood aging and develop strategies to restore healthy immune cell production, with the long-term goal of improving treatments for aging-related disorders and blood cancers.
